Home Health Management of Parkinson’s Disease Deep Brain Stimulation: A Randomized Clinical Trial
Objective: Evaluate the efficacy of home health DBS postoperative management in an effort to reduce travel burden and improve access. Background: The travel required to…Should Amantadine DR/ER Be Considered Prior to Device-Aided Therapies for Parkinson’s Disease?
Objective: Evaluate delayed release/extended release amantadine (AMT DR/ER) capsules for motor complications in patients meeting 5-2-1 criteria for device-aided therapies (DAT) in advanced Parkinson disease.…CVT-301 (levodopa inhalation powder): meta-analysis of safety in patients with Parkinson’s disease (PD)
Objective: Safety results from a phase 3, double-blind study of CVT-301 in patients with PD were combined with results from a 4-week, phase 2b, double-blind,…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Characterization of Acute Nausea During Dose Titration
Objective: Characterize acute episodes of nausea experienced by patients with Parkinson’s disease (PD) receiving apomorphine sublingual film (APL) for the on-demand treatment of “OFF” episodes.…Impulse Control Disorders Following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Randomized Controlled Trial
Objective: To assess frequency and outcomes of impulsivity in study participants receiving bilateral subthalamic deep brain stimulation (STN-DBS) for treatment of Parkinson’s Disease (PD) who…CLE-600: Treating nocturnal and early morning OFF symptomology in Parkinson’s disease with the OLAR® platform
Objective: Development of a treatment for nocturnal and early morning OFF symptomology in Parkinson’s disease. Background: Levodopa Parkinson’s disease (PD) treatment is limited by its…The PD-1102 trial in advanced Parkinson’s disease: safety and clinical outcomes from a 3-year phase 1b study of AADC gene therapy administered via a posterior approach
Objective: To present 3-year safety and clinical outcome data from a phase 1b, open-label trial of VY-AADC01 (NBIb-1817) for Parkinson’s disease (PD) patients with motor…Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of entacapone: findings from the real-world OPTIPARK study
Objective: This post-hoc analysis evaluated the effectiveness of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations (MF) according to baseline use of entacapone…OPTIMIPARK Questionnaire:a tool to optimize treatment in Parkinson´s disease.
Objective: To validate the OPTIMIPARK questionnaire as a tool to help the clinician in the adjustment of dopaminergic treatment in Parkinson´s disease(PD). Background: At early…Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of safinamide: findings from the real-world OPTIPARK study
Objective: This post-hoc analysis evaluated the effectiveness of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations (MF) according to baseline use of safinamide…
- « Previous Page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- …
- 132
- Next Page »